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Abstract: Diabetic Retinopathy (DR) is a major complication of diabetes and is a leading cause of blindness in
western countries. DR has been considered a microvascular disease, and the blood-retinal barrier breakdown is
a hallmark of this disease. The available treatments are scarce and not very effective. Despite the attempts to
control blood glucose levels and blood pressure, many diabetic patients are affected by DR, which progresses
to more severe forms of disease, where laser photocoagulation therapy is needed. DR has a huge psychological
impact in patients and tremendous economic and social costs. Taking this into account, the scientific
community is committed to find a treatment to DR. Understanding the cellular and molecular mechanisms
underlying the pathogenesis of DR will facilitate the development of strategies to prevent, or at least to delay
the progression of the disease. The involvement of the polyol pathway, advanced glycation end products,
protein kinase C and oxidative stress in the pathogenesis of DR is well-documented, and several clinical trials
have been conducted to test the efficacy of various drugs. More recent findings also demonstrate that DR has
characteristics of chronic inflammatory disease and neurodegenerative disease, which increases the
opportunity of intervention at the pharmacological level. This review presents past and recent evidences
demonstrating the involvement of different molecules and processes in DR, and how different approaches and
pharmacological tools have been used to prevent retinal cell dysfunction.
Keywords: Diabetic retinopathy, blood-retinal barrier, polyol pathway, advanced glycation end products (AGEs), protein
kinase C (PKC), oxidative stress, inflammation, neurodegeneration.
INTRODUCTION microaneurysms, hemorrhages, lipid exudates, cotton-wool
spots and neovascularization (proliferative DR). In the case
of proliferative DR, the new vessel walls are weak, allowing
the blood to leak out of the vessels, which results in
vitreous hemorrhage and subsequent detachment of the retina
[3]. Visual impairment is usually associated with the later
stages, and is mainly due to the formation of new vessels on
the surface of the retina and macular edema.
It is estimated that diabetes affects around 200 million
people worldwide, and the number of people affected by
diabetes will continue to increase over the next years.
Particularly, the prevalence of type 2 diabetes (non-insulin-
dependent) is increasing at an alarming rate. Diabetic
Retinopathy (DR) is one of the most common complications
of diabetes, and is the leading cause of blindness in western
countries [1,2]. DR has been considered a microvascular disease, but
recent findings clearly indicate that other components of the
retina, such as neurons and glial cells, may be also affected
[4,5]. Thus, multiple cell types in the retina are affected by
diabetes and multiple pathogenic processes occur at the same
time.
Despite recent progresses in understanding the cellular
and molecular mechanisms underlying the pathogenesis of
DR, the disease is still neither preventable nor curable. The
scientific community is committed to this field of research,
and there has been a concerted effort to develop new
strategies to treat DR. Hyperglycemia is considered to be the
primary pathogenic factor in the development of DR.
However, the mechanisms by which high blood glucose
levels cause the disease and its progression are not clear yet.
In fact, the development of therapeutic strategies to treat DR
strictly depends on our understanding of the pathogenic
process.
After 15 years with diabetes, approximately 80% of
patients have retinopathy, and therefore prevention is the key
word. With a good control of glycemia, blood pressure and
normalization of lipids, it is possible to delay the onset and
progression of the disease, but in some cases, it is difficult
to achieve good metabolic control. Laser photocoagulation is
usually the recommended treatment for patients with
proliferative DR or severe macular edema, but in a high
percentage of patients, retinopathy continues to progress and
the treatment needs to be repeated. Photocoagulation is a
rather aggressive technique since it destroys the retina [2].
Therefore, the development of non-invasive therapies to
prevent and treat DR is needed, and remains a priority for
eye research. In fact, since the appearance of laser surgery,
there have been no major advances in the treatment of this
disease, despite several clinical trials on a variety of drugs.
DR is clinically characterized by microvascular
dysfunction, with basement membrane thickening of retinal
vessels, loss of pericytes and endothelial cells, blood-retinal
barrier (BRB) breakdown, capillary non-perfusion,
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In addition to morphological alterations, various
biochemical and molecular changes have been identified in
human diabetic retinas and in animal models [6].
Hyperglycemia stimulates protein kinase C (PKC), polyol
pathway, formation of advanced glycation end products
(AGEs) and cellular oxidative stress [7]. A large body of
evidence also indicates that DR has many features of
neurodegeneration and chronic inflammation, such as
increased nitric oxide production, intracellular adhesion
molecule-1 (ICAM-1) upregulation and leukostasis [4,8]. All
these processes and molecules are potential therapeutic
targets, and in recent years, several drugs have been tested in
patients with diabetes.
The VEGF gene produces alternatively spliced mRNA
variants, leading to at least three distinct major VEGF
isoforms [28]. The biological effects of VEGF are mediated
by at least two tyrosine kinase receptors, also known as
VEGF receptor 1 (VEGF-R1) and VEGF receptor 2 (VEGF-
R2) [28,29].
Several lines of evidences suggest that VEGF induces
retinal permeability by altering tight junction protein
complexes. Both diabetes and VEGF reduce occludin and
ZO-1 content in various experimental models and alter tight
junction assembly [30,31]. Also, VEGF might regulate
vessel permeability by increasing the phosphorylation of
tight junction proteins, namely occludin and ZO-1 [30].
This review will focus on molecular and cellular changes,
and on biochemical pathways activated by hyperglycemia in
the retina, as potential targets in the treatment of DR. Also,
studies involving human subjects in which some drugs with
potential use in the therapy of this disease have been tested,
will be presented and discussed.
The identification of mediators that regulate VEGF-
induced BRB breakdown is important for a potential
pharmacological intervention. It was shown that VEGF
overexpression and BRB breakdown are correlated with
increased expression of both endothelial and neuronal nitric
oxide synthase (eNOS and nNOS). Moreover, inhibiting
nitric oxide synthase or scavenging peroxynitrite could
prevent the alterations in barrier permeability [16,32,33].
Increased activity and expression of inducible NOS (iNOS)
and cyclooxygenase-2 (COX-2) were also found in diabetic
retinas [34]. These observations indicate that nitric oxide and
peroxynitrite formation are involved in the pathogenesis of
DR.
BLOOD-RETINAL BARRIER BREAKDOWN AND
NEOVASCULARIZATION: ANTI-VEGF THERAPY
AND THE POSSIBLE USE OF CORTICOSTEROIDS
Homeostasis is essential for the normal function of the
retina and is maintained by both inner and outer BRB that
control water and solute flux to the retinal parenchyma and
protect the retina from compositional fluctuations within the
blood. The BRB is formed by highly specialized endothelial
or epithelial cells, which restrict the diffusion of molecules
by an assembly of proteins that constitutes the functional
tight junctions between cells [9]. Tight junctions are
composed of several transmembrane proteins, such as
occludin, claudins and junctional adhesion molecule (JAM).
Other proteins, localized in peripheral cytoplasm, including
zonula occludens (ZO)-1, ZO-2 and ZO-3, act through
multiple protein-protein interactions, and organize the tight
junction complex and provide the interaction with
components of the cytoskeleton [10,11].
Capillary occlusion occurring in the early stages of DR is
believed to play an important role in the progression of the
disease [35]. Capillary occlusion could lead to hypoxia of
retinal tissue, promoting an upregulation of growth factors,
such as VEGF, and consequent formation of new vessels
[36,37]. Therefore, in addition to its role as a permeabilizing
agent, VEGF is also involved in the formation of new
vessels in diabetic retinas. It is well-known that VEGF is
upregulated by hypoxia and stimulates endothelial cell
migration and proliferation [38,39]. Multiple stimulatory
factors may contribute to the development of retinal
neovascularization, but VEGF plays a critical role. Signaling
through VEGF receptors is both necessary and sufficient for
development of retinal neovascularization [40-42].
The breakdown of BRB is an early event in DR, leading
to macular edema in more advanced stages of the pathology
[12]. Vascular endothelial growth factor (VEGF) is
considered to be a major factor in the breakdown of BRB
[13]. However, other permeabilizing factors such as
histamine, interleukin-1 beta (IL-1b) and tumor necrosis
factor alpha (TNF-a ) have also been implicated [14-16].
VEGF is increased in the eyes of diabetic patients and
diabetic rats at the early stages of DR, and this observation
was correlated with increased vascular permeability [17-19].
VEGF has also been found in aqueous and vitreous humor
of patients with proliferative DR [20].
Blocking VEGF synthesis and vitreal injection of anti-
VEGF antibodies prevented retinal neovascularization in
animal models [20]. Many approaches to inhibit VEGF
action are being considered. One strategy is to inject
relatively large inhibitors, such as aptamers or Fab fragments
of anti-VEGF antibodies directly into the eye [43,44].
Another strategy is to avoid repeated intraocular injections
by systemic administration of small molecule VEGF
antagonists [41,42,45]. Soluble VEGF receptors provide a
specific way to reduce VEGF bioavailability, and some
studies have demonstrated that the extracellular domain of
VEGF-R1 has antiangiogenic activity [46,47]. However, a
disadvantage is that soluble VEGF-R1 is rapidly cleared.
Saishin et al. [21] found that the clearance slows when
ligand-binding domains of VEGF receptors linked to the Fc
portion of IgG are used, and neovascularization is
suppressed. Also, inhibition of VEGF receptor tyrosine
kinase activity seems to be promising, not only for cancer
research but also for a potential therapeutic use in the
treatment of the vasoproliferative phase of DR. Studies
using mouse models of oxygen-induced retinopathy and
Inhibition of VEGF with specific VEGF-neutralizing
soluble constructs can prevent the increase in BRB
permeability induced by diabetes, clearly indicating that
VEGF has a key role in this pathology [19,21]. Growth
factors, such as transforming growth factor alpha (TGF-a ),
TNF-a , insulin-like growth factor 1 (IGF-1), and
interleukins, AGEs and reactive oxygen species (ROS) have
been shown to be upregulated in DR, and induce VEGF
overexpression [22-27]. However, it is not well-understood
how these factors lead to VEGF overexpression.
The Old and New Drug Targets in Diabetic Retinopathy  Current Drug Targets - CNS & Neurological Disorders,  2005, Vol. 4, No. 4    423
ischemia-induced retinopathy have shown that local
treatment with specific receptor kinase inhibitors decrease
retinal neovascularization [48,49].
and increased the regeneration of damaged axons [61,62].
However, clinical trials with sorbinil only caused small
increases in conduction velocity [63-65]. Toxicity may pose
a problem in the use of some AR inhibitors, as was
demonstrated with sorbinil, which caused hypersensitivity
reactions in 10 percent of patients. Even though the benefits
of these drugs are limited, they may have a role in
preventing diabetes-related diseases, such as DR, or in
easing the symptoms of some patients.
Pharmacological attenuation of VEGF effects and the use
of corticosteroids in the treatment of macular edema
associated with DR are being studied. Corticosteroids, a
class of substances with anti-inflammatory properties, have
been demonstrated to inhibit the expression of the VEGF
gene. The platelet derived growth factor (PDGF)–induced
expression of VEGF in cultures of human aortic vascular
smooth muscle cells was inhibited by corticosteroids in a
concentration-dependent manner [50]. Also, a recent study
showed that intravitreous administration of triamcinolone
reduces VEGF levels in the vitreous of patients with various
degrees of DR and diabetic macular edema, and causes
regression of active neovascularization [51]. In vitro studies
demonstrated that corticosteroids increase the expression of
tight junction proteins, namely occludin and ZO-1, and they
can also reverse occludin phosphorylation [52,53].
INTERVENTION AT THE LEVEL OF ADVANCED
GLYCATION END PRODUCTS (AGEs)
Glucose can react with free amino groups to form Schiff
base adducts and Amadori products. In biological systems,
these intermediates are freely reversible and therefore exist in
equilibrium that is proportional to the amount of free
glucose. As a result, the levels of Amadori products in
diabetic patients are usually two- to threefold higher than in
their non-diabetic counterparts, but they do not accumulate
indefinitely in long-lived macromolecules and there is no
correlation between these adducts formation on tissues and
diabetic complications [66].
The evidences presented here demonstrates the
importance of VEGF in the pathogenesis of DR. In the early
phase of DR, it acts as a permeabilizing factor, increasing
the permeability of BRB, and at the later stages, it promotes
neovascularization. Several studies pointed out that it is
possible to regulate VEGF activity using different strategies,
and in some cases, the results obtained are quite promising.
The application of these approaches to humans still needs to
be validated, but the advances obtained in cancer research
and treatment in recent years may be helpful to people
suffering from DR. It must be emphasized that VEGF does
not act alone, and other molecules regulating or regulated by
VEGF might be also considered good molecular targets,
since it will also be possible indirectly to block, totally or
partially, VEGF action.
Non-enzymatic condensation reactions between reducing
sugars and amino groups or N-terminal groups also lead to
advanced glycation end products formation [67], which can
accumulate in cells over prolonged periods. AGEs formation
on proteins, lipids, and DNA can have serious consequences
for macromolecular function during diabetes and aging [68-
70]. Moreover, AGEs can interact with specific AGEs
receptors and lead to oxidative stress and activation of
nuclear factor kappa B (NF-k B) [71].
AGEs are known to accumulate in the diabetic retina
where they may have important effects on retinal vascular
cell function, as determined by a growing number of in vitro
and in vivo studies [72,73]. Pentosidine is one of the AGEs
found in the vitreous of patients with proliferative DR, and
there is a high correlation between its levels and IL-6 levels
[74], suggesting that increased formation of AGEs in the
vitreous may be involved in the development of DR by
inducing the production of IL-6 from retinal Müller cells.
Accumulation of fructosyl-lysine was found in the kidney,
retina and peripheral nerve of diabetic rats [75]. AGEs and/or
late Amadori products have been localized in the neuroglia
of diabetics [76], and they may have important, albeit poorly
understood effects on neural dysfunction during retinopathy.
AGEs were also reported to induce apoptosis in retinal
pericytes in culture [77].
INHIBITING ALDOSE REDUCTASE ACTIVITY
In the retina, the glycolytic pathway is overwhelmed in
prolonged hyperglycemia, which favors the production of
sorbitol by aldose reductase (AR). Sorbitol is further
oxidized to fructose by sorbitol dehydrogenase, increasing
the NADH/NAD+ ratio [54]. This increase creates a state
called “pseudohypoxia”, which may favor increased free
radical production, decreased nitric oxide synthesis and
defective DNA repair [55,56].
Polymorphisms of AR gene may account for individual
variations in the susceptibility to DR [57]. Aldose reductase
seems to be a key enzyme in the development of DR, since
several AR inhibitors (ARIs), such as alresatin, sorbinil,
ponalrestat, tolrestat, epalrestat, fidarestat and zenalestat had
proven to be effective in experimental diabetes [58,59].
However, studies with diabetic patients have failed to prove
any success. The Sorbinil Retinopathy Trial Research Group
attempted to show that sorbinil could slow the progression
of DR, however, the results failed to demonstrate the
efficacy of this drug at the end of the three-year follow-up
study [60]. Moreover, sorbinil was poorly tolerated, and
significant secondary effects were observed, which make the
use of this drug in humans problematic.
The therapeutic strategies that can be addressed using the
prominent pathological role of AGEs are: prevention of
AGEs formation, reduction of AGE receptor-ligand
interactions or breaking established AGE crosslinks.
Aminoguanidine, a potent inhibitor of AGE crosslinks, has
been shown to be effective at preventing capillary closure,
microaneurysm formation, basement membrane thickening
and depletion of nitric oxide synthase [78-83].
Aminoguanidine was evaluated in a multicenter clinical trial
where it achieved significant lowering of urinary albumin
and slowed the progression of nephropathy and retinopathy
[84]. Nevertheless, it is important to mention that this drug
has many non-specific effects, including the inhibition of
In humans with diabetic neuropathy and in diabetic
animals, ARIs improved the velocity of nerve conduction
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inducible nitric oxide synthase and semicarbazide-sensitive
amine oxidase [85,86].
PKC b  activation might act as both modulator of VEGF
action and stimulator of VEGF expression [102]. Intravitreal
injection of VEGF induces retinal vessel permeability in
non-diabetic rats, and this effect can be suppressed by
intravitreal or oral administration of LY333531, a specific
inhibitor of PKCb , or the general PKC inhibitor
GF109203X [103]. In addition, the intravitreal injection of a
PKC activator could induce the breakdown of BRB in non-
diabetic rats [103]. Otherwise, the inhibition of PKC
prevents glucose-induced increase in VEGF expression in
vitro [104,105]. The intraperitoneal administration of a PKC
inhibitor decreased retinal vessel permeability and retinal
VEGF expression in diabetic rats [105]. Also, intravitreal
injection of GF109203X decreased VEGF expression and
retinal permeability in diabetic rats [106]. So, PKC
inhibitors can prevent or reverse BRB breakdown by
inhibiting VEGF expression or by interfering at the level of
the intracellular signal transduction cascade initiated by
VEGF.
The use of AGEs crosslink breakers allows pre-
accumulated AGEs clearance via the kidney. AGEs crosslink
breakers, such as N-phenacylthiazolium bromide and ALT-
11, attack dicarbonylderived crosslinks in vitro and reduce
tissue AGEs in experimental diabetes [87-89]. ALT-711 has
been shown to ameliorate myocardial stiffness in aged dogs
[90] and improved the ability of the carotid artery to expand
during systole in diabetic rats [88]. In clinical trials, ALT-
711 improved arterial compliance in aged patients with
measurable cardiovascular stiffening [84].
Although several lines of evidence demonstrate that
therapies against AGEs have beneficial effects in several
complications of diabetes, there is not a particular drug that
has proved to be effective, and without significant secondary
effects in the treatment of DR.
Benfotiamine: High Expectations
The adhesion of leukocytes to endothelial cells is
increased in diabetes, and this process seems to be mediated
by adhesion molecules, such as ICAM-1 [107]. Some
studies have suggested that PKC is also involved in the
expression of adhesion molecules in endothelial cells. Lane
et al. [108] demonstrated that PKC upregulates ICAM-1
expression in HUVECs and increases leukocyte adhesion to
endothelial cells. The expression of vascular cell adhesion
molecule-1 (VCAM-1) also seems to be regulated by PKC
[109]. Furthermore, PKC inhibition has been shown to
reduce glucose-induced leukocyte adhesion in vitro [110],
and the PKC inhibitor LY333531 inhibits leukocyte
entrapment in diabetic retina [111].
Benfotiamine is a lipid-soluble derivative of vitamin B1
with high bioavailability that can block the production of
AGEs [91,92]. It was reported that high-dose therapy with
thiamine and benfotiamine suppressed the accumulation of
AGEs during diabetic nephropathy, and therefore may be a
new approach to prevent the development of diabetic
complications [93]. In a clinical trial with diabetic patients,
benfotiamine used in combination of vitamin B6/B12
improved nerve conduction velocity in the peroneal nerve
[94]. Benfotiamine and thiamine also prevented apoptosis
induced by high glucose in human umbilical vein
endothelial cells (HUVECs) and bovine retinal pericytes
[95]. In the retina, it was suggested that benfotiamine
prevents activation of the hexosamine pathway and the
diacylglycerol-protein kinase C (DAG-PKC) pathway, and
intracellular AGEs formation [96]. Whether benfotiamine can
be used in the pharmacological prevention or treatment of
the vascular complications of diabetes remains to be
established.
These studies conducted in a variety of experimental
models in vitro and in vivo have demonstrated the
involvement of PKCb  in DR. These observations have led
to a possibly promising therapy using oral inhibitors of
PKC b  isoform. Clinical trials with PKCb  antagonists are
currently under way, to test their toxicity and effectiveness
in suppressing diabetic complications. However, preliminary
data with LY333531, there appears to be no effect on
retinopathy progression in patients with moderate to severe
non-proliferative DR [112]. These results could be explained
by consideration that the causes of diabetic complications are
multifactorial in nature, with other factors such oxidative
stress, glycation end products and others also playing key
roles. This reinforces the idea that DR treatment probably
requires a multidrug therapy.
PROTEIN KINASE C: ANOTHER IMPORTANT
PLAYER IN DR
The protein kinase C family is a large group of
serine/threonine kinases. Their function is to phosphorylate
specific sites on protein targets, which is an important
regulatory system for activating or deactivating enzymes,
receptor pathways, and transcription factors controlling gene
expression. Different enzymes of this class require the
specific activation by second messengers, such as
diacylglycerol (DAG). The PKC family is widely distributed
throughout the body, and a generalized inhibitor of PKC is
likely to have serious systemic consequences. However, the
effect of specific inhibitors for a small class of PKC might
have specific targets (such as organs or biochemical
pathways), and therapeutical effects could be more effective
and with less side effects.
ANTIOXIDANTS AS POTENTIAL
THERAPEUTICAL AGENTS IN DR
Oxidative stress is believed to play a significant role in
the pathogenesis of DR. Since the beginning of the last
decade, a large body of evidence has demonstrated and
confirmed that ROS play an important role in the
development of DR, and therefore strategies conducted to
prevent the deleterious effects caused by free radicals have
been considered as potential treatments of this disease.
The activation of PKC b  isoform (PKC b ) has been
implicated in the pathogenesis of DR [97-100]. It has been
shown that DAG levels are increased and PKCb  is activated
in the retinas from diabetic animals, and also in bovine
retinal endothelial cells (BRECs) exposed to high glucose
[99-101].
Increased oxidative stress might result from increased
generation of free radicals and/or from an impairment of the
antioxidant defense system. Several reports have shown that
diabetes increases the formation of free radicals in the retina
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[113,114]. The excess of glucose leads to glucose auto-
oxidation, and this is a main source of free radicals.
Increased levels of thiobarbituric acid-reacting substances
(TBARS), which are markers of oxidative stress, and
decreased levels of superoxide dismutase (SOD) and
glutathione peroxidase, were found in serum samples
obtained from diabetic patients, when compared with control
subjects, but no significant association was found between
the levels of these substances and the severity of retinopathy
[115]. In diabetic rats, an increase in the levels of TBARS
and a decrease in glutathione levels in the retina were also
found [116]. The increase in the levels of TBARS,
glutamate and nitric oxide were inhibited in rats receiving a
diet supplemented with a mixture of antioxidants [117,114].
Increased levels of TBARS were also found in BRECs
exposed to high glucose concentrations, and the presence of
the antioxidant N-acetyl cysteine inhibited the formation of
TBARS [114]. It seems that mitochondria are responsible
for the elevation in the production of superoxide anions in
diabetic retinas, and in cultured retinal Müeller cells and
endothelial cells exposed to high levels of glucose [118].
group of results clearly indicates that oxidative stress is
involved in microvascular cell loss in the course of DR.
The administration of a mixture of antioxidants also
inhibited the activation of NF-kB, a transcription factor
involved in the regulation of a large number of genes,
suggesting that the beneficial effects of antioxidants might
involve inhibition of NF-kB activation [124].
As mentioned before, the possibility that endogenous
free radical scavengers are diminished in diabetic retinas
must also be demonstrated. Almost two decades ago,
Jennings et al. [125] demonstrated that the levels of ascorbic
acid, a scavenger of free radicals, are significantly decreased
in diabetic patients when compared to controls, suggesting
that diabetics may be less able to prevent oxidative damage
due to increased oxidative stress. The activities of
glutathione reductase, glutathione peroxidase, SOD and
catalase were decreased in the retinas of diabetic or
galactosemic rats, but the activities of glutathione synthetase
and gamma-glutamyl cysteine synthetase were unaffected
[126]. Administration of vitamin C and E prevented the
inhibition of those enzymes activities in diabetic animals,
but in galactosemic rats, only SOD activity was restored to
normal values. The levels of glutathione were also decreased
in the retinas of non-obese, spontaneous non-insulin-
dependent Goto-Kakizaki diabetic rats [127]. Using cultured
BRECs and pericytes, Paget et al. [70] have shown that
high glucose decreases glutathione peroxidase activity in
endothelial cells, but no changes were observed in retinal
pericytes.
Increased levels of VEGF in the retinas of diabetic rats
were attenuated by two antioxidants, alpha-lipoic acid and
taurine [119], suggesting that oxidative stress is involved in
the overproduction of VEGF. These antioxidants also
decreased the formation of lipid peroxidation products, such
as malondialdehyde and 4-hydroxyalkenal.
As with VEGF, the increase in the activity of the polyol
pathway caused by hyperglycemia is associated with the
breakdown of blood-retinal barrier. The increase in the
activity of this pathway, mainly due to increased activity of
aldose reductase, may be one origin of excessive ROS
production [120]. Fidarestat, an inhibitor of aldose
reductase, arrested lipid peroxidation in the retinas of
diabetic rats, essentially due to an increase in the activity of
several antioxidant enzymes rather than changes in reduced
glutathione, oxidized glutathione, ascorbate or dehydro-
ascorbate concentrations. In BRECs, fidarestat also inhibited
the production of ROS induced by high glucose [120].
These results indicate that increased aldose reductase activity
contributes to retinal oxidative stress and retinal damage.
The expression of several antioxidant enzymes was also
determined by quantitative RT-PCR assay in purified
pericytes, isolated from diabetic and non-diabetic donors.
The pericytes isolated from the retinas of diabetic donors
highly expressed a death protease, which is indicative of the
activation of an apoptotic pathway in these cells. In diabetic
pericytes, an upregulation of glutathione peroxidase, a
downregulation of glutathione reductase and CuZnSOD were
observed, while the mRNA levels of MnSOD and catalase
did not differ significantly from pericytes isolated from non-
diabetic donors [128]. These results suggest that there is an
impairment of the antioxidant defense system in diabetic
pericytes, but the upregulation of glutathione peroxidase
indicates that there is a compensatory mechanism against
increased levels of free radicals. These observations clearly
demonstrate that the breakdown of the antioxidant system in
pericytes from diabetic retinas is involved in pericyte
dropout, which is considered a hallmark of DR and is one of
the earliest changes observed in diabetic retinas.
Apoptosis of retinal pericytes and endothelial cells
contributes to retinal microvessels, obliteration and increased
permeability of the BRB. Recently, it was found that
caspase-3, an executioner enzyme of apoptosis, is activated
in the retinas of alloxan diabetic rats and in cultured
endothelial cells and pericytes exposed to high glucose
[121]. Feeding rats with a diet supplemented with several
antioxidants, including Trolox, alpha-tocopherol, N-acetyl
cysteine, ascorbic acid, beta-carotene and selenium, or
incubating cells with the antioxidants, inhibited the increase
of caspase-3 activity, suggesting that oxidative stress is
involved in the activation of caspase-3 and apoptosis of
endothelial cells and pericytes. Also, long-term
administration of alpha-lipoic acid to diabetic rats has
beneficial effects on capillary cell apoptosis and on the
number of acellular capillaries in the retina, due to inhibition
of nitrotyrosine and oxidatively modified DNA
accumulation [122]. The number of pericytes present in
retinal vessels was also partially restored in diabetic rats
treated with trolox, an amphipathic antioxidant [123]. This
The evidence presented here clearly demonstrates that
oxidative stress plays a key role in DR. Increased production
of ROS, formation of TBARS and lipid peroxidation,
associated with a decrease in the activity of several
antioxidant enzymes and in the amount of endogenous
molecules with antioxidant properties, are characteristics of
diabetic retinas or retinal cells exposed to high levels of
glucose. Antioxidants prevent or at least inhibit, some
retinal metabolic abnormalities and pathological changes
induced by hyperglycemia, such as the breakdown of BRB,
microvascular cell death and the formation of acellular
capillaries, as demonstrated by using in vitro and animal
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models. Therefore, it is reasonable to think that an
antioxidative therapy may be useful in the prevention of
retinal damage, and some antioxidants may be considered as
an adjunct therapy to prevent vision loss in diabetic patients.
The mechanisms by which antioxidants inhibit the
development of retinopathy caused by diabetes are nor clear
yet, and need further investigation. It seems that free radicals
act at various levels inside the cells, increasing the
production of VEGF and activating NF-k B, for example. A
key element taken from animal studies indicates that
increasing the diversity of anti-oxidants provides more
effective protection than using a single antioxidant. Whether
antioxidants can prevent or delay retinal damage caused by
diabetes in humans, has not been established yet, since the
studies with human subjects are somewhat controversial.
ANGIOTENSIN CONVERTING ENZYME (ACE)
INHIBITORS
The renin-angiotensin system (RAS) plays a central role
in blood pressure regulation. Most diabetic patients are also
affected by hypertension [144], and elevated serum levels of
angiotensin converting enzyme (ACE) have been found in
type 1 diabetic subjects with retinopathy, especially in those
with proliferative retinopathy, which suggests that elevated
ACE levels may be a potential cause of retinal vascular
damage in diabetes [145-148]. Indeed, it was shown that
strict control of blood pressure and the use of an ACE
inhibitor is effective in reducing the progression of DR and
vision loss [149].
Hypertension might contribute to the progression of DR
by increasing endothelial shear stress and the release of
VEGF that follows stretching of the vessel walls [150]. The
EURODIAB Controlled Trial of Lisinopril in Insulin
Dependent Diabetes (EUCLID) has shown that the ACE
inhibitor lisinopril, significantly reduces the progression of
retinopathy in non-hypertensive patients with type-1 diabetes
[151]. Other studies using angiotensin II receptor
antagonists, have shown that losartan reduces leukocyte
entrapment in retinal vessels of rats [152], and candesartan
reduces VEGF and retinal abnormalities in diabetic rats
[153]. In addition, it was shown that treatment with ACE
inhibitors attenuates vitreous levels of VEGF in patients
with proliferative DR, probably by interference with a local
effect of angiotensin II [154]. These observations suggest
that inhibition of the renin-angiotensin system in the eye
may have useful effects in the prevention of DR, and some
effects may be independent of blood pressure reduction.
Clinical studies have shown that high doses of vitamin E
can apparently reverse some of changes in the retinal vessels,
probably because vitamin E decreases PKC and DAG levels
[129]. Treatment of diabetic patients with Vitamin E
normalizes retinal blood flow, appearing to be effective in
normalizing retinal hemodynamic abnormalities [130]. It
was also shown that chronic administration of Vitamin E
improves metabolic control and reduces protein glycation
[131,132]. The potential use of selenium and Ginkgo biloba
in the treatment of DR has also been considered, but there is
no substantial experimental or clinical evidence clearly
showing the beneficial effects of these compounds
[133,134].
Calcium dobesilate (CD; Doxium) has been used in the
treatment of DR in more than 60 countries [135-137].
Calcium dobesilate is considered a highly effective
angioprotective drug, but its mechanism(s) of action is still
poorly understood. Calcium dobesilate decreases retinal
albumin leakage, the formation of advanced glycation end
products and VEGF overexpression in diabetic rat retinas
[138]. These effects seem to be correlated with its
antioxidant properties. In fact, CD was shown to scavenge
hydroxyl radicals in vitro at therapeutically relevant
concentrations, and to scavenge superoxide anions, but at
higher concentrations [139]. Also, CD enhances the levels of
glutathione in human peripheral blood mononuclear cells
exposed to a highly reducing sugar 2-deoxy-D-ribose, thus
decreasing the lipid peroxidation [140]. Although these
findings suggest that the main mechanism of action of CD
is as a free radical scavenger, other mechanisms might be
involved in its vasoprotective effects.
FIGHTING INFLAMMATION
In recent years, DR has been considered a low-grade
chronic inflammatory condition. The levels of cytokines,
including IL-1b , IL-6, and IL-8, are increased in the vitreous
of diabetic patients with proliferative DR [155,156], and IL-
1b  levels are increased in the retina of diabetic rats [157].
The expression of different isoforms of nitric oxide synthase,
particularly the iNOS, and cycloxigenase-2 is also increased
in diabetes with a subsequent increase in nitric oxide and
prostaglandins [157-159]. Increased leukocyte adhesion,
ICAM-1 expression, vascular permeability, and capillary
occlusion, features commonly found in inflammation, have
also been suggested to be involved in the progression of DR
[158,160-162].Several clinical studies have shown that after long-term
oral treatment CD delays the progression of DR. Calcium
dobesilate decreases blood viscosity and microvascular
hyperpermeability of retinal vessels, thus stabilizing BRB
permeability and preventing both intra and extraretinal
hemorrhages [135, 136, 141, 142]. Beneficial effects were
also observed in animal studies [138,143].
Leukocytes, including monocytes, neutrophils and some
lymphocytes, adhere to the retinal vascular endothelium
early in both experimental and human DR [160,163-166].
Further, its occurrence coincides temporally and spatially
with the appearance of BRB breakdown, capillary non-
perfusion and endothelial cell death [107,163,165]. The
expression of adhesion molecules, especially ICAM-1 and
VCAM-1, are increased in diabetic retinas and are correlated
with leukocyte adhesion [160,164,167,168]. However, a
recent study in human subjects has reported that the levels of
vascular ICAM-1 are similar in the retinas of control and
diabetic subjects, suggesting that other factors might be
involved in the increase of leukostasis and capillary
occlusion [169].
All the evidence presented here indicates that
antioxidants may provide additional benefits in reducing the
risk for developing DR. However, there is at present no
substantial and clinical evidence to justify the clinical use of
these drugs. Nevertheless, patients with diabetes might be
encouraged to consume fruits and vegetables enriched in
antioxidants, or even supplements of vitamins.
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ICAM-1 is a member of the immunoglobulin
superfamily of adhesion molecules whose ligands include
leukocyte b 2-integrins CD11a/CD18 and CD11b/CD18.
When neutralizing antibodies directed against ICAM-1 are
administered into diabetic animals, the leukocyte-related
pathology is dramatically reduced [107, 165]. Similarly,
when the bioactivity of the ICAM-1 counter receptor CD18
is inhibited, diabetic retinal leukocyte adhesion is potently
suppressed [170]. In addition, CD18 and ICAM-1 knockout
mice exhibit significantly fewer adherent leukocytes in the
retinal vasculature at 11 and 15 months after induction of
diabetes with STZ. This condition is associated with fewer
damaged endothelial cells and lesser vascular leakage. Also,
galactosemia causes pericyte and endothelial cell loss and
formation of acellular capillaries, and these changes are
significantly reduced in CD18- and ICAM-1-deficient mice
[171].
TNF-a  retinal levels induced by diabetes, but neither aspirin
nor etanercept altered VEGF levels. Aspirin and etanercept
also decreased the levels of ICAM-1 induced by diabetes
[160].
New strategies for drug development include proteins
involved in the synthesis of pro-inflammatory cytokines,
such as caspase-1, formerly known as IL-1b -converting
enzyme (ICE), the enzyme responsible for the production of
the pro-inflammatory cytokines IL-1b  and IL-18. Results
revealed that activation of caspase-1 occurs early in the retina
of diabetic mice and diabetic patients [186]. The activation
of caspase-1 has been demonstrated in several
neurodegenerative diseases, and inhibition of caspase-1 has
been shown to have beneficial effects suppressing these
diseases [187,188]. Minocycline, a second-generation
chemically modified tetracycline, was able to prevent the
activation of capase-1 in the retina of diabetic mice [8]. This
compound and others that inhibit caspase-1 could be
potential candidates to treat DR.
The formation of acellular capillaries and the subsequent
retinal ischemia lead to upregulation of VEGF. The injection
of VEGF into normal non-diabetic eyes recapitulates many
of the retinal vascular changes triggered by diabetes,
including leukocyte adhesion, vascular permeability, and
capillary non-perfusion [172-175]. VEGF is expressed early
in diabetic retinas [176,177], and increases the expression of
ICAM-1 and leukocyte adhesion [160]. Also, VEGF
upregulation in diabetes correlates with the increased
expression of surface integrin and integrin-mediated adhesion
[160].
As mentioned before, glucocorticoids are anti-
inflammatory drugs. These drugs are currently used in the
treatment of many clinical conditions including asthma and
rheumatoid arthritis [189]. The anti-inflammatory activity of
glucocorticoids is mostly associated with repression of pro-
inflammatory genes such as cytokines, inhibition of pro-
inflammatory transcription factors such as NF-k B, and
induction of apoptosis in leukocytes recruited to the site of
inflammation [189]. In addition, in vitro studies showed
that triamcinolone, a corticosteroid already in use in clinical
trials, downregulates ICAM-1 expression induced by TNF- a
or interferon gamma (IFN-g ) [190].
VEGF increases retinal eNOS expression [160] probably
by activation of the serine/threonine protein kinase
AKT/PKB, leading to an increase in nitric oxide production
and ICAM-1 upregulation [178]. So, the inhibition of
endogenous VEGF would lead to the downregulation of
retinal ICAM-1 through a reduction in eNOS expression. In
fact, retinal nitrite levels were upregulated in diabetic
animals and were normalized via the inhibition of
endogenous VEGF. Moreover, the inhibition of eNOS via
systemic administration of NG-nitro-L-arginine methyl ester
(L-NAME) reduced diabetic-induced leukocyte adhesion
[160].
A large body of evidence shows that inflammation has a
key role in the pathology of DR, but only recently, the
concept of a low-grade chronic inflammatory disease
associated with DR, has been started to be accepted.
Therefore, further studies testing the efficacy of anti-
inflammatory drugs in the prevention and progression of DR
are needed. It is important to note that these drugs may be
targeted to act at different steps of the inflammatory process.
ASPIRIN: YES OR NO?
Increased levels of cytokines, such as TNF-a  and IL-1b ,
cause cell death and tissue damage. Cytokines induce
endothelial cytokine expression and upregulation of adhesion
molecules that leads to leukocyte adhesion and endothelial
cell death [179]. Recent studies have shown that IL-1b
accelerates apoptosis of retinal capillary cells through
activation of NF- k B, and the process is exacerbated in high-
glucose conditions [180].
Aggregation of platelets is increased in diabetes, and it
had been proposed as the underlying abnormality that
triggers capillary occlusion [191]. Platelet microthrombi was
shown to occur in retinal capillaries of diabetic patients
several decades ago [192]. Some years later, it was observed
that patients with rheumatoid arthritis receiving high doses
of aspirin tended to have less severe DR [193]. Indeed, large
thrombi occur more often in retinas from diabetic patients
than in control retinas [194]. Recently, Kern and Engerman
found that treatment of diabetic dogs with aspirin reduced
the number of acellular capillaries and retinal hemorrhages
after five years of diabetes [195].
In diabetes, oxidative stress is increased in the retina and
other tissues [181], and it is closely linked to apoptosis in
various cells [182]. Reactive oxygen species are considered a
strong stimulus for the release of cytokines [183], and IL-1b
itself can trigger signaling cascades resulting in excessive
production of ROS [184].
Platelets by themselves are no longer thought to be of
prime importance in blocking retinal capillaries. Changes in
endothelial cells and leukocytes are also believed to be
responsible for capillary occlusion (for review see [163]).
Experiments with diabetic rats showed that high dose aspirin
reduces leukocyte adhesion to diabetic retinal capillaries,
arterioles and venules [16]. Aspirin also reduced the
Cytokines are attractive targets for the development of
novel anti-inflammatory drugs. Soluble TNF-a  receptor/Fc
construct (TNFR-Fc, etanercept) is used in rheumatoid
arthritis [185]. High-dose aspirin and etanercept, each
reduced diabetes-induced leukocyte adhesion and suppressed
BRB breakdown in diabetic rats [160]. Aspirin decreases
428     Current Drug Targets - CNS & Neurological Disorders,  2005, Vol. 4, No. 4 Ambrósio et al.
expression of integrins on surface of leukocytes and the
adhesion molecule, ICAM-1, in the capillary wall. Other
effects included reduction of eNOS levels and less
production of TNF- a . Taking this into account, there seems
to be ample reason for using aspirin in DR.
symptoms of neuronal dysfunction of the retina, occurring
within 2 years after the onset of DR in humans.
Recent reports demonstrate that diabetes affects retinal
neurons, probably prior to vascular changes. Neuronal cell
loss occurs by apoptosis in both diabetic animals and
diabetic patients with a concomitant decrease in the
thickness of the inner retina [209]. Several other reports
showed that neurodegeneration occurs in the diabetic retina,
both in animal models and in humans [210-212]. Recently,
it was reported that when the RTP801 gene (previously
isolated as a hypoxia-inducible factor, HIF-1) was knocked
out in an animal model of retinopathy of prematurity,
neuronal death and neovascularization were attenuated,
indicating that RTP801 gene may be a novel therapeutic
target for treatment of retinopathy of prematurity and DR
[213].
The effectiveness of aspirin in clinical trials has been
controversial. The statistically significant inhibitory effect of
the drug on retinopathy in one clinical trial [196] was
shown, but this study was not considered to be clinically
important, since there was only a slight beneficial effect. In
contrast, in a larger clinical trial, aspirin had no significant
beneficial effects [197]. However, in view recently published
literature, this view may have to be reconsidered, and high
dose aspirin may become one of the possible additions to
preventive treatment of DR.
WILL BE ANTIHISTAMINES USEFUL IN DR?
Managing the Glutamatergic System in the Retina
As with VEGF, histamine is considered to be a
permeabilizing factor, and acts on cells through four types of
receptors, H1, H2, H3 and H4. Histamine has been
implicated in BRB dysfunction in both experimental
diabetes and diabetic patients [198-200]. The synthesis of
histamine is increased in the retinas of diabetic rats
[201,202], and the mRNA levels of histidine decarboxylase,
the enzyme responsible for histamine synthesis, are increased
in retinal neurons and glia [203]. These data suggest the
involvement of neural cells in diabetes-induced vascular
leakage, possibly mediated by histamine. Inhibition of
histidine decarboxylase decreases histamine overproduction
induced by diabetes, and similar effects were observed with
insulin administration in experimental diabetes, indicating
that insulin modulates histamine metabolism [201]. Also,
drugs blocking histamine receptors, such as
diphenhydramine-HCl, ranitidine and astemizole, have been
shown to reduce the leakage of retinal vessels in diabetic rats
and humans [200,202].
Glutamate is the most important excitatory amino acid in
the retina [214], but overactivation of ionotropic glutamate
receptors can lead to cell death [215]. Glutamate is
implicated in several neurodegenerative diseases in the
Central Nervous System, including the retina, such as
retinitis pigmentosa and glaucoma [216,217]. The role that
glutamate plays in DR is still poorly understood, but several
reports have demonstrated that the glutamate concentration
increases in diabetic rat retinas [117,218]. Glutamate
concentrations in the vitreous of diabetic patients and
animals are also increased [219-221], probably due to an
increase in the release of glutamate.
Under normal conditions, glutamate is kept in low
concentrations mainly due to a glial-specific enzyme,
glutamine synthetase (GS), which has a neuroprotector role
against retinal injury due to excessive glutamate [222]. In
diabetic rats, GS activity and content are decreased [223],
and glutamate uptake is decreased as well [224], which may
be related to glial changes occurring within the diabetic
retina. These changes can lead to excitotoxic levels of
glutamate in the retina, which may be responsible for
changes in retinal neurotransmission and vision loss.
Some evidences suggest that histamine increases the
permeability of BRB because it downregulates the
expression of tight junction proteins, particularly ZO-1
expression [204]. Studies exploring the involvement of
histamine on the permeability of BRB are not abundant, but
it has also been shown that blocking histamine receptors
attenuates blood-brain barrier permeability and ameliorates
cerebral blood flow disturbances [205]. It is therefore
important to clarify the role of histamine on the breakdown
of BRB, since it might be another tool used against DR.
Therapies using glutamate receptor antagonists, such as
memantine, an uncompetitive NMDA-receptor antagonist,
have been shown to be of great value in some neurological
disorders such as Alzheimer’s disease. The results of a phase
III clinical study reported that memantine (20 mg/day) had a
notable tolerability among patients and it was found to be
efficacious for moderate to severe Alzheimer’s disease [225].
In fact, it was already reported that memantine was able to
reduce NMDA-induced increase in nitric oxide and TBARS
in rat retinas [117], indicating that memantine or similar
compounds could be used to prevent increased oxidative
stress induced by elevated glutamate [117]. In another retinal
model, memantine was partially protective against glutamate
excitotoxicity for retinal ganglion cells [226].
DIABETIC RETINOPATHY: TREATING A
NEURODEGENERATIVE DISEASE?
Despite being usually considered a vascular disease,
recent evidence suggests that DR may also be a
neurodegenerative disorder [4,5]. Retinal neurons comprise
photoreceptors, bipolar cells, amacrine cells, horizontal cells
and ganglion cells. Photoreceptors receive light and
transduce photons into electrical impulses, which converge
ultimately on ganglion cells to transmit signals to the brain.
Therefore, vision loss must result from impaired neuronal
function. In fact, loss of color sensitivity [206,207] and
contrast sensitivity [208] has been reported as early
NitroMemantines are second-generation memantine
derivatives, designed to have enhanced neuroprotective
efficacy without sacrificing safety, by using the memantine
binding site for the targeted delivery of nitric oxide to a
second modulatory site on the NMDA receptor [227]. It was
already observed that patients taking nitroglycerin for other
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medical purposes may be resistant to glaucomatous visual
field loss [228], but further studies need to be performed to
investigate the potential of these drugs in the prevention of
DR.
expressed primarily in neurons. Neurotrophic factors use a
variety of signal transduction systems, involving primarily
the intrinsic kinase activity of the Trk receptors, leading to
activation of various serine–threonine kinases [239].
INSULIN AS A TROPHIC FACTOR
Neurotrophic factors have the potential to provide new
therapies for neurodegenerative diseases such as Alzheimer’s
disease, Parkinson’s disease, peripheral neuropathy, and
optic neuropathy. Neurotrophins are known to have survival
and neurite outgrowth-promoting activity in the central and
peripheral nervous systems [240]. Neuronal components of
the retina contains receptors for the different neurotrophins,
and they can prevent the loss of ganglion cells after retinal
injury [241,242]. BDNF levels are decreased in the retina of
diabetic animals, and intraocular administration of BDNF
rescued dopaminergic amacrine cells from neurodegeneration
[243], demonstrating its therapeutical potential. However, a
clinical trial performed in patients with diabetic neuropathy,
in which BDNF was injected subcutaneously, failed to
demonstrate a significant beneficial effect in nerve
conduction [244]. Further studies will be necessary to better
understand the role of neurotrophins in the retina, and
possibly to use them as neuroprotective agents.
Recent evidences show that both vascular and neural
retinal cells express insulin receptors (IR) (for review see
[229]). Insulin action begins when ligand binds the receptor
on a  subunits, which induces conformational changes and
activates the intrinsic tyrosine kinase activity in the b
subunits in the cytoplasm. The IR autophosphorylates on
tyrosine residues within its tyrosine kinase domain and
initiates a cascade of phosphorylation-dephosphorylation,
and translocation events within the cell.
In bovine retina, IR were found in all retinal layers,
predominantly located on the dendritic processes of neurons
and in Müller cells [230]. Because the retina expresses the
IR at similar levels to other classically responsiveness
organs, it must be considered a major target for insulin
action. Insulin has a protective role in the retina, since it was
reported that in the absence of insulin, there is an increase in
ganglion cell apoptosis [231], and cell death is reduced in
the presence of insulin in developing chick retinas [232]. In
diabetic rats, insulin can rescue retinal neurons from
apoptosis by reducing caspase-3 enzyme activity [233].
CONCLUDING REMARKS
It is important to emphasize that the potential damage
caused by elevated glucose on retinal function is not a
consequence of an isolated factor or pathway, but it is the
sum of various mechanisms (Fig. 1), and a consequence of
multiple interactions between different molecules and
pathways. The strategies designed to prevent, treat or ease
the symptoms of DR must take this into account. Probably,
the best way to deal with DR is using a multidrug therapy,
and not using only a single drug. Figure 1 summarizes
current knowledge about DR, that is, processes and
molecules considered to be involved in the pathogenesis of
DR. Pharmacological tools that have been used to prevent or
restore retinal dysfunction are also indicated.
The therapeutic action of insulin in DR is still
controversial. Some clinical studies demonstrated that
intensive insulin therapy might cause a transient worsening
of retinopathy in some individuals [234-236]. It was also
reported that knockout mice for a vascular endothelial cell
specific insulin receptor were protected from retinal
neovascularization [237]. Recently, Poulaki et al. [105]
found that subcutaneous insulin implants, delivering low-
dose (2 units) of insulin daily, increased blood–retinal
barrier permeability and VEGF expression in rats with short-
term streptozotocin diabetes.
In recent years, important advances were achieved in
order to clarify the pathogenesis of DR, but the puzzle is far
from being completed. Genetic differences between patients
might also complicate this unsolved problem. In any event,
new strategies and new drugs are being tested in
experimental models, and in some cases, the results obtained
are promising. In the past, several promising drugs did not
prove to be effective in humans, and therefore, we must keep
developing and characterizing new pharmacological tools
effective in the treatment of DR.
On the other hand, the study by The Diabetes Control
and Complications Trial/Epidemiology of Diabetes
Interventions and Complications Research Group reported
that intensive insulin treatment of type 1 diabetes patients
reduced the risk of progression of retinopathy and
nephropathy [238]. The same study also concludes that
intensive insulin therapy adopted early in the course of early
onset diabetes appears to have a protective effect that lasts
for many years, and is superior to the adoption of intensive
therapy later in the course of the disease. However, more
experiments must be performed and if so, systemically
administered insulin may be a direct pharmacological
intervention for the retina and other tissues, including the
kidneys and peripheral nerves. After understanding the
importance of insulin action, new drugs may be developed
to enhance the actions of insulin and IR.
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PROTECTING NEURONS WITH NEUROTROPHINS
ABBREVIATIONS
The neurotrophin family of ligands contains nerve
growth factor (NGF), brain-derived neurotrophic factor
(BDNF), neurotrophin-3, and neurotrophin-4/5.
Neurotrophins and their receptors, TrkA, TrkB and TrkC, are
ACE = Angiotensin converting enzyme
AGEs = Advanced glycation end products
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Fig. (1). Processes and molecules involved in the pathogenesis of DR as potential drug targets. Pharmacological tools with possible
application in the therapy of DR.
AR = Aldose reductase JAM = Junctional adhesion molecule
ARIs = AR inhibitors NF-k B = Nuclear factor kappa B
BDNF = Brain-derived neurotrophic factor NGF = Nerve growth factor
BRB = Blood-retinal barrier NMDA = N-methyl-D-aspartate
BRECs = Bovine retinal endothelial cells nNOS = Neuronal nitric oxide synthase
CD = Calcium dobesilate PDGF = Platelet derived growth factor
COX-2 = Cyclooxygenase 2 PKC = Protein kinase C
DAG = Diacylglycerol PKC b = PKC beta isoform
DAG-PKC = Diacylglycerol-protein kinase C RAS = Renin-angiotensin system
DR = Diabetic Retinopathy ROS = Reactive oxygen species
eNOS = Endothelial nitric oxide synthase SOD = Superoxide dismutase
EUCLID = EURODIAB Controlled Trial of Lisinopril 
in Insulin-Dependent Diabetes
TBARS = Thiobarbituric acid-reacting substances
TGF-a = Transforming growth factor alpha
GS = Glutamine synthetase TNF- a = Tumor necrosis factor alpha
HUVECs = Human umbilical vein endothelial cells TNFR-Fc = TNF-a  receptor/Fc construct
ICAM-1 = Intracellular adhesion molecule 1 VCAM-1 = Vascular cell adhesion molecule 1
ICE = IL-1b -converting enzyme VEGF = Vascular endothelial growth factor
IGF-1 = Insulin-like growth factor VEGF-R1 = VEGF receptor 1
IFN-g = Interferon gamma VEGF-R2 = VEGF receptor 2
IL = Interleukin ZO = Zonula occludens
IL-1b = Interleukin-1 beta
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